An interventional study of Constraint-Induced Movement Therapy (CIMT) and Transcutaneous auricular vagus nerve stimulation (taVNS) in Perinatal Brain Injury, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 8 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Hypoxia-Ischemia, Brain with a site in United States — 27 open to participants now, 34 under way, 1 of them phase 3. Hypoxia-Ischemia, Brain · United States.
Among the 84 studies in Hypoxia-Ischemia, Brain with a site in United States, this one is the 42nd largest by planned enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2026, is one of 21 with no phase, reaches primary completion later than 15 of the 33 other live ones, and was the 82nd registered.
261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.
Browse Hypoxia-Ischemia, Brain studies →27 of the 84 studies in Hypoxia-Ischemia, Brain with a site in United States are open now. Recruiting first, the newest first:
CergenX Limited · Sites in United States, Ireland
Ages 36 wk+
Artemis AI Labs · Sites in United States
Healthy volunteers
Healing Hope International · Sites in United States
Ages 4–12
Boston Children's Hospital · Sites in United States
Yale University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.
This study: 8 Months to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 14 · Phase 3 3 · Phase 4 1
First in 1999; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 50 across 156 interventional studies indexed under Hypoxia-Ischemia, Brain.
Median enrollment 32 across the 52 interventional studies, 78 across the 31 observational. Of the 42 that completed or were terminated, 21 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 84 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 4 studies filed under Hypoxia-Ischemia, Brain — fewer than ten, so there is no comparison to draw.
17 of the studies in Hypoxia-Ischemia, Brain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05778188Phase 3ReAlta Life Sciences, Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia | 2026-12 |
| NCT05568264Shirley Ryan AbilityLabEffects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit | 2026-12-31 |
| NCT02664831MaineHealthImmunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS) | 2027-01 |
| NCT05361070University of California, San FranciscoNeonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy | 2027-02-28 |
| NCT02621944University of FloridaMelatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia | 2027-03 |
Add all 17 to your calendar (.ics) → With an account.
Among the 84 studies in Hypoxia-Ischemia, Brain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is for infants and toddlers between 8 and 24 months old who use one arm and/or hand differently following a perinatal brain injury. This is a time when investigators think they can best help improve how the brain controls movement. Investigators are testing whether the combination of transcutaneous auricular vagus nerve stimulation (taVNS) with 40 hours of constraint-induced movement therapy (CIMT) can help infants move their weaker arm and hand better and make the brain pathways for movement stronger.
Primary Objective • To evaluate the feasibility of using spTMS to elicit motor-evoked potentials (MEPs) in infants with hemiplegic cerebral palsy (CP) due to perinatal brain injury and to determine whether baseline MEP characteristics predict motor response to a 40-hour intervention combining taVNS with CIMT.
Exploratory Objective:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Therapy sessions in this study will take 4 hours a day, 5 days a week for 2 weeks (40 hours total CIMT). Sticker like sensors (electrodes) are placed just inside and outside the child's left earlobe at the start of the session to deliver the taVNS. During daily therapy sessions, the taVNS will be on whenever the child moves their free arm, for up to 2.5 minutes at a time.
Behavioral: Constraint-Induced Movement Therapy (CIMT) · Device: Transcutaneous auricular vagus nerve stimulation (taVNS)
CIMT involves placing a mitt constraint on the stronger arm and hand while encouraging your child to use the weaker arm and hand during intensive therapy sessions.
Stimulates a nerve by the ear, called the vagus nerve, that may enhance learning motor skills.
Proportion of participants in whom MEPs can be elicited reliably at baseline (presence/absence)
Motor-evoked potentials (MEPs) are electrical responses recorded from a muscle following a brief magnetic pulse delivered to the brain using single-pulse transcranial magnetic stimulation (spTMS). This outcome measures the proportion of participants in whom a reliable MEP can be elicited at baseline and serves as a measure of the feasibility of assessing corticospinal connectivity in infants with perinatal brain injury.
Time frame: baseline (Day 1)
Completion rate of spTMS sessions
This outcome measures the proportion of planned spTMS assessment sessions that are successfully completed at baseline, post-intervention, and 3-month follow-up. Completion rates will be used to evaluate the feasibility, tolerability, and practicality of conducting repeated spTMS assessments in infants and toddlers with perinatal brain injury.
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
Baseline MEP Amplitude
MEP amplitude will be reported in millivolts (mV), measured from electromyography recordings of the target muscle.
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
Percent change in Mini-Assisting Hand Assessment (mini-AHA) score from baseline to end of treatment
The mini-AHA evaluates how effectively infants with unilateral upper extremity impairment use their affected hand during bimanual play activities. Scores are reported on a standardized 0-100 scale, with higher scores indicating greater functional use of the affected hand and lower scores indicating less functional use.
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
Change in Quality of Upper Extremity Skills Test (QUEST) score from baseline
This is a measure of movement, scored in several domains: dissociated movement (joint mobility), grasp (holding and manipulating objects), protective extension (reflex reactions), and weight bearing assessments. It is scored from 0 to 100 where higher scores mean better movement. Change in QUEST score from baseline will be used to assess changes in upper extremity function following the intervention.
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
Bayley Scales of Infant Development (Bayley-4; Fine Motor subtest)
The Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Fine Motor subtest evaluates fine motor skills, including reaching, grasping, object manipulation, and hand-eye coordination. Scores are standardized based on age and range from 1 to 19, with a normative mean of 10 and standard deviation of 3. Scores in the range of 8-12 are generally considered within the typical range for age. Higher scores indicate more advanced motor development.
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
Bayley Scales of Infant Development (Bayley-4; Gross Motor subtests)
The Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Gross Motor subtest evaluates gross motor skills, including posture, sitting, crawling, standing, walking, and other age-appropriate movement abilities. Scores are standardized based on age and range from 1 to 19, with a normative mean of 10 and standard deviation of 3. Scores in the range of 8-12 are generally considered within the typical range for age. Higher scores indicate more advanced motor development.
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
Gross Motor Function Measure (GMFM-88)
The Gross Motor Function Measure-88 (GMFM-88) evaluates gross motor function across five domains: lying and rolling, sitting, crawling and kneeling, standing, and walking, running, and jumping. Items are scored on a 4-point scale and converted to dimension and total scores ranging from 0 to 100. Higher scores indicate better gross motor function and greater ability to perform age-appropriate motor activities.
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
MEP Amplitude
Motor-evoked potential (MEP) amplitude measures the strength of the muscle response produced after a brief magnetic pulse is applied to the brain using single-pulse transcranial magnetic stimulation (spTMS). Larger amplitudes indicate stronger communication between the brain and the target muscle. MEP amplitude will be reported in millivolts (mV).
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
MEP Threshold
Motor-evoked potential (MEP) threshold is the minimum level of magnetic stimulation needed to produce a muscle response. Lower thresholds generally indicate that the pathway between the brain and muscle can be activated more easily. MEP threshold will be reported as a percentage of maximum stimulator output (%MSO).
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
Cortical Map Topography
Cortical map topography describes the location and distribution of brain areas that produce muscle responses when stimulated using single-pulse transcranial magnetic stimulation (spTMS). Changes in the size, location, or organization of these areas over time may reflect changes in brain connectivity and neuroplasticity.
Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.
Of 46 non-industry interventional studies with no phase under Hypoxia-Ischemia, Brain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 63. This study's planned 8 months is below that.
Counting every sponsor, half of 47 studies reached it within 33 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison →